There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (NASDAQ:CLSD) and Blueprint Medicines (NASDAQ:BPMC) with bullish sentiments.
Clearside Biomedical (CLSD)
Wedbush analyst Liana Moussatos reiterated a Buy rating on Clearside Biomedical today and set a price target of $29. The company’s shares opened today at $5.51, close to its 52-week low of $5.03.
According to TipRanks.com, Moussatos is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.4% and a 33.7% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Clearside Biomedical is a Moderate Buy with an average price target of $29, representing a 426.3% upside. In a report released today, Cowen & Co. also assigned a Buy rating to the stock.
.
See today’s analyst top recommended stocks >>
Blueprint Medicines (BPMC)
Cowen & Co. analyst Marc Frahm maintained a Buy rating on Blueprint Medicines today. The company’s shares opened today at $60.80, close to its 52-week low of $57.44.
According to TipRanks.com, Frahm is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -18.8% and a 11.1% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Merrimack Pharmaceuticals, Adaptimmune Therapeutics, and Gritstone Oncology Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Blueprint Medicines with a $104 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
